Ratings Healwell AI Inc.

Equities

AIDX

CA42249X1006

Delayed Toronto S.E. Other stock markets 10:34:07 2024-04-24 am EDT			5-day change	1st Jan Change
1.53 ^CAD	-2.55%		+6.25%	+104.00%

Apr. 04	HEALWELL AI Unit Pentavere Publishes Paper Validating Use of Generative AI to Identify Rare Lung Cancer Patients	MT
Apr. 04	HEALWELL AI Brief: Says Its Pentavere Achieved Validation of Generative AI for Preventative Care Through Landmark Publication	MT

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
For the past twelve months, EPS forecast has been revised upwards.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The opinion of analysts covering the stock has improved over the past four months.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Healthcare Facilities & Services

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
HEALWELL AI INC.	+104.00%	130M	-	-
AIER EYE HOSPITAL GROUP CO., LTD.	-23.64%	15.55B		B+
BANGKOK DUSIT MEDICAL SERVICES	+1.80%	12.05B		B
IHH HEALTHCARE	+2.82%	11.5B		B+
APOLLO HOSPITALS ENTERPRISE LIMITED	+10.15%	10.69B		B+
ENCOMPASS HEALTH CORPORATION	+25.09%	8.26B		B
RAMSAY HEALTH CARE LIMITED	-0.40%	7.79B		A-
MOUWASAT MEDICAL SERVICES COMPANY	+22.54%	7.31B		D
THE ENSIGN GROUP, INC.	+5.67%	6.75B		B-
GLOBAL HEALTH LIMITED	+45.79%	4.51B		-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes